VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
HROW
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HROWHarrow Health, Inc.
$41.15$1.5B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksHROWBalance Sheet

Harrow Health, Inc. (HROW) Balance Sheet

20Y historyFree accessUpdated daily

The company's financial position appears increasingly precarious as the debt-to-equity ratio surged to 10.61 in 2026Q1, accompanied by a $184.1M deficit in retained earnings.

HROW Balance Sheet

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06
Total Current Assets226.38M211.75M189.65M139.07M118.26M60.66M40.98M36.77M32.84M8.81M14.75M5.87M9.06M15.73M10.04M160.96K351.95K1.67M5.33M4.24M27.43K
Cash & Short-Term Investments94.64M72.93M47.25M82.77M101.86M50.67M32.75M29.95M28.06M4.02M8.85M2.69M8.21M15.58M10.04M146.16K291.46K1.59M5.11M3.71M27.43K
Cash Only94.64M72.93M47.25M74.08M96.27M42.17M4.1M4.75M6.64M4.02M8.85M2.69M8.21M15.58M10.04M146.16K291.46K1.59M5.11M3.71M27.43K
Short-Term Investments0008.68M5.59M8.5M28.64M25.2M21.42M000000000000
Accounts Receivable101.26M110.89M116.6M36.49M6.39M4.52M2.66M2.01M1.96M1.62M2.92M840K81.32K00000000
Days Sales Outstanding125.26148.65213.21102.326.3222.7519.8814.3317.3322.1453.4631.5617.88--------
Inventory16.5M13.52M10.7M10.87M6.54M4.22M3.96M3.3M1.83M2.25M1.84M1.41M372.74K00000000
Days Inventory Outstanding53.6272.6679.32100.0694.0684.5199.9971.9440.5260.7868.3599124.47--------
Other Current Assets1.33M14.4M3.41M1.75M118K92K1.05M922K125K124K200K150K116.63K50.1K596.28K14.8K60.49K0000
Total Non-Current Assets193.16M187.73M199.32M172.68M39.12M37.67M16.49M22.32M16.61M15.11M12.49M8.26M1.19M26.89K670.38K03381.39K2.45K00
Property, Plant & Equipment10.72M11.04M12.29M12.44M11M9.08M10.67M11.93M6.38M6.21M7.29M2.66M243.4K26.89K12.55K03381.39K2.45K00
Fixed Asset Turnover24.00x24.66x16.24x10.46x8.05x7.99x4.58x4.29x6.49x4.31x2.73x3.66x6.82x0.37x7.97x------
Goodwill332K332K332K332K332K332K332K332K2.23M2.23M2.23M2.47M331.62K00000000
Intangible Assets182.11M175.17M186.7M159.91M25.84M17.13M2.52M2.34M3.06M2.86M2.97M3.13M610.99K00000000
Long-Term Investments0000011.13M2.97M7.71M4.95M3.51M00000000000
Other Non-Current Assets01.18M001.95M12.45M07.71M4.95M302K0000657.83K000000
Total Assets419.54M399.48M388.97M311.75M157.38M98.33M57.47M59.09M49.45M23.92M27.25M14.13M10.24M15.76M10.71M160.96K352.29K1.67M5.34M4.24M27.43K
Asset Turnover0.70x0.68x0.51x0.42x0.56x0.74x0.85x0.87x0.84x1.12x0.73x0.69x0.16x0.00x0.01x------
Asset Growth %33.72%2.7%24.77%98.09%60.05%71.08%-2.73%19.48%106.76%-12.22%92.82%37.97%-35.02%47.22%6551.46%-54.31%-78.93%-68.66%25.82%15358.47%-
Total Current Liabilities91.44M96.3M91.34M49.34M18.63M9.72M10.8M12.28M11.9M5.77M9.9M5.37M1.56M650.63K709.56K1.86M335.04K1.09M763.99K750.24K3.08K
Accounts Payable26.13M35.35M38.76M21.42M6.44M5.17M3.65M7.41M4.97M3.88M3.54M3.41M787K261.92K342.47K218.61K73.63K681.01K556.39K696.34K0
Days Payables Outstanding136.27189.96287.3197.2792.61103.6891.99161.46109.71105131.36238.87262.81----235.39K---
Short-Term Debt915K887K0806K003.9M1.77M3.25M598K4.43M21K24.11K001.43M00000
Deferred Revenue (Current)345K788K44K0113K16K057K119K29K91K65K1.68K00100K80K0000
Other Current Liabilities52.6M59.27M021.66M01.16M66K293K564K-545K-251K660K7.47K50K141.92K000000
Current Ratio2.48x2.20x2.08x2.82x6.35x6.24x3.79x2.99x2.76x1.53x1.49x1.09x5.80x24.18x14.14x0.09x1.05x1.53x6.98x5.65x8.92x
Quick Ratio2.30x2.06x1.96x2.60x6.00x5.81x3.43x2.72x2.61x1.14x1.30x0.83x5.57x24.18x14.14x0.09x1.05x1.53x6.98x5.65x8.92x
Cash Conversion Cycle42.6131.355.235.0927.773.5827.88-75.19-51.87-22.08-9.54-108.32-120.46--------
Total Non-Current Liabilities299.75M251.09M228.33M192.41M111.51M77.68M19.85M19.38M12.8M15.53M10.91M10.14M531.78K0286.69K1.75M1.06M00696.34K0
Long-Term Debt292.09M243.18M219.54M183.17M104.17M71.65M12.38M12.22M12M14.01M7.94M8.59M00001.06M0000
Capital Lease Obligations32.08M7.91M8.79M6.52M7.33M6.02M6.67M6.36M0720K1.32M1K19K00000000
Deferred Tax Liabilities0000000000936K1.05M000000000
Other Non-Current Liabilities0002.71M00800K800K800K800K719K500K512.78K00000000
Total Liabilities391.19M347.39M319.67M241.75M130.14M87.4M30.65M31.67M24.7M21.3M20.82M15.52M2.09M650.63K709.56K1.86M1.39M1.09M763.99K750.24K3.08K
Total Debt300.67M251.98M228.83M190.5M112.23M77.96M23.53M20.99M15.25M15.33M13.69M8.36M43.08K001.43M1.06M0000
Net Debt206.02M179.05M181.58M116.42M15.96M35.79M19.43M16.24M8.61M11.31M4.83M5.67M-8.17M-15.58M-10.04M1.28M764.02K-1.59M-5.11M-3.71M-27.43K
Debt / Equity10.61x4.84x3.30x2.72x4.12x7.13x0.88x0.77x0.62x5.86x2.13x-0.01x--------
Debt / EBITDA6.31x4.38x10.46x16.47x23.63x23.24x10.44x--------------
Net Debt / EBITDA4.33x3.11x8.30x10.06x3.36x10.67x8.62x--------------
Interest Coverage0.88x1.60x0.40x0.04x0.26x0.62x0.33x-0.28x-1.91x-4.02x-5.55x-13.22x-2670.26x--217.33x-11.72x-44.63x---1.74x-57.50x
Total Equity28.35M52.09M69.3M70M27.24M10.93M26.83M27.42M24.75M2.62M6.43M-1.39M8.15M15.11M10M-1.7M-1.04M577.21K4.57M3.49M24.36K
Equity Growth %-108.57%-24.83%-1.01%156.98%149.2%-59.26%-2.15%10.78%846.5%-59.34%564.4%-116.99%-46.06%51.16%688.02%-63.74%-279.87%-87.37%30.98%14229.91%-
Book Value per Share0.761.421.942.150.990.411.041.041.040.130.50-0.140.891.752.22-4.27-2.631.4812.3415.780.13
Total Shareholders' Equity28.71M52.45M69.65M70.36M27.59M11.29M27.18M27.71M24.75M2.62M6.43M-1.39M8.15M15.11M10M-1.7M-1.04M577.21K4.57M3.49M24.36K
Common Stock37K37K35K35K30K27K26K26K24K21K19K10K9.26K8.97K6.77K15.9K15.93K15.65K15.56K13.73K1.6K
Retained Earnings-184.13M-156.52M-151.38M-133.9M-109.49M-95.41M-77.4M-74.04M-74.21M-88.84M-76.85M-57.76M-41.87M-31.75M-24.1M-18.52M-17.47M-14.94M-10.38M-7.08M-56.84K
Treasury Stock000000000000000000000
Accumulated OCI000-409K0000-4.36M-2.76M-1.35M-300K-45.44K0-2.94K000000
Minority Interest-355K-355K-355K-355K-355K-355K-355K-293K0000000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Excessive leverage and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Leverage Escalation Limits Strategic Flexibility

As reported in recent financial filings, Harrow's debt-to-equity ratio has surged to 10.61 in 2026Q1, reflecting a significant increase from the 4.84 level observed in 2025Q4, which indicates that the company's reliance on debt financing has reached a level that may constrain future operational flexibility.

The rapid accumulation of debt to fund acquisitions appears to be outpacing the company's ability to generate sufficient equity through retained earnings. Investors should monitor whether this high leverage profile necessitates further dilutive equity raises to service interest obligations or support ongoing commercialization efforts.

Equity Erosion Through Persistent Losses

Based on the company's historical balance sheet data, retained earnings have deteriorated to a deficit of $184.1M as of 2026Q1, a trend that underscores the persistent operational losses and the resulting erosion of shareholder equity over the past ten quarters.

The consistent decline in retained earnings suggests that the company's core business model has yet to achieve the scale required for profitability. This trend warrants further investigation into whether the current capital structure can sustain long-term growth without further eroding the value attributable to common shareholders.

Liquidity Buffer Faces Increasing Pressure

According to the most recent quarterly reports, Harrow's cash position of $94.6M in 2026Q1 provides a temporary buffer, yet the company's liquidity profile remains sensitive to the high cash burn rates associated with its aggressive branded pharmaceutical commercialization strategy and debt service requirements.

While the current ratio of 2.48 appears adequate on the surface, the underlying cash burn suggests that the company may face liquidity constraints if product adoption does not accelerate. The reliance on external financing to maintain these cash levels implies that the company's liquidity is not currently self-sustaining.

Hidden Risks in Asset Valuation

As indicated by the company's financial disclosures, the reliance on equity-method investments and the potential for goodwill impairment risk create a distortion in the reported asset base, which may mask the true volatility of the company's underlying ophthalmic pharmaceutical intellectual property.

The presence of significant non-consolidated interests suggests that headline asset figures may not accurately reflect the cash-generating potential of the core business. Analysts should be cautious, as any downward revaluation of these holdings could further weaken an already strained balance sheet.

HROW — Frequently Asked Questions

Quick answers to the most common questions about buying HROW stock.

What are the total assets of Harrow Health, Inc. (HROW)?

As of 2025, Harrow Health, Inc. (HROW) had total assets of $399.5M including $211.8M in current assets.

How much debt does Harrow Health, Inc. (HROW) have?

Harrow Health, Inc. (HROW) carries total debt of $252.0M, offset by $72.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Harrow Health, Inc.?

Harrow Health, Inc. (HROW) has total shareholders' equity (book value) of $52.4M ($1.42 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Harrow Health, Inc.'s current ratio and liquidity?

Harrow Health, Inc. (HROW) reported a current ratio of 2.20x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.